---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-041616"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2026-09-04T22:26:16+00:00"
generated_at: "2026-09-08T10:05:56.731421+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vivos converts $2.86M debt into 11.4M shares; dilution up to 52% of prior outstanding

## Summary
- Twelve exchange agreements with Streeterville Capital dated Aug 31, 2026 convert $2,861,270 of note principal into up to 11,445,080 shares at avg $0.25/share.
- After exchanges, Streeterville Note balance reduced to ~$3.7M from original $8.225M (June 9, 2025).
- Pre-exchange shares 22,164,313; post-settlement 33,609,393, a ~52% increase from dilution.
- No cash proceeds; Section 3(a)(9) exemption; shares free-trading with tacked holding period to Jun 9, 2025.
- Beneficial ownership limited to 4.9%; later exchanges require sell-down of prior shares.

## SEC filing metadata
- accession: 0001493152-26-041616
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2026-09-04T22:26:16+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315226041616/0001493152-26-041616-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315226041616/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-041616
- JSON: https://secwatch.observer/filing/0001493152-26-041616.json
- Plain text: https://secwatch.observer/filing/0001493152-26-041616.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.